发现一种强效的APOBEC3B抑制剂,可增强抗肿瘤免疫并降低炎症毒性
Discovery of a Potent APOBEC3B Inhibitor to Augment Antitumor Immunity and Reduce Inflammatory Toxicity
Ning Haoming, Yang Kejia, Zhang Yu, Liu Junjun, Zhu Xueqin, Chen Chunxia, Dong Qingyu, Shang Wenzhi, Chen Xiaoshuang, Yang Xin, Liang Rui, Li Yang, Qian Yuzhen, Sun Yixuan, Zhou Xiuman, Liu Yi, Li Na
Journal:JOURNAL OF MEDICINAL CHEMISTRY
IF:7.3
DOI:10.1021/acs.jmedchem.6c01416
PMID:42720465
Published:2026-08-14
research field:分子生物学癌症研究细胞生物学胃肠病学
Abstract
APOBEC3B (A3B), a key driver of cancer mutagenesis, has emerged as a promising therapeutic target to be ablated to enhance antitumor immunity while reducing intestinal inflammation. Starting from SMC247 (3, 5-diiodotyrosine), a kelp-derived natural product, we identified the optimized analogue SMC247-9 as a potent A3B inhibitor, with an IC 50 of 50 pM and K D value of 300 pM. SMC247-9 reduced cellular A3B abundance and promoted IL-15 expression in tumor cells, thereby relieving tumor cell-mediated suppression of CD8 + T cells in an IL-15-dependent manner. In immunocompetent mice, SMC247-9 suppressed tumor growth in the immune checkpoint blockade (ICB)-responsive MC38 model and synergized with anti-PD-L1 in the ICB-resistant TC-1 model. SMC247-9 also attenuated macrophage chemotaxis and ameliorated anti-PD-1-exacerbated DSS-induced colitis-like intestinal inflammation. These findings support A3B-targeted pharmacologic intervention as a strategy to enhance antitumor efficacy while reducing inflammatory toxicity in cancer immunotherapy.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


